Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06011187
Other study ID # APHP 220817
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 1, 2024
Est. completion date December 30, 2026

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact ALEXANDRE JOOSTEN, MD PhD
Phone +33145213441
Email joosten-alexandre@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Goal directed fluid therapy (GDFT) or "Personalized fluid therapy" may benefit high-risk surgical patients but these strategies are infrequently implemented. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist that have been correlated with poor patient outcomes. Recently, an "Assisted Fluid Management" (AFM) system has been developed to help ease some of the work associated with GDFT protocol implementation. The AFM system may help increase GDFT protocol adherence while leaving direction and guidance in the hands of the care providers. This artificial intelligence-based system can suggest administration of fluid boluses, analyse the hemodynamic effects of the bolus, and continually re-assess the patient for further fluid requirements. To date, there are no large outcome study using this AFM system. The primary objective of this trial is thus to evaluate the impact of this AFM system to guide fluid bolus administration on a composite of major postoperative complications in high-risk patients undergoing high-risk abdominal surgery.


Description:

Many trials have indicated that goal-directed fluid therapy (GDFT) strategies or more recently "personalized fluid therapy" may benefit high-risk surgical patients but these strategies are infrequently implemented. It has also been shown that without any goal or protocol for fluid resuscitation, large inter- and intra-provider variability exist that have been correlated with poor patient outcomes. Even under ideal study conditions, strict adherence to GDFT protocols is hampered by the workload and concentration required for consistent implementation. Hemodynamic monitors and protocols alone do not enable optimal fluid titration to be provided consistently to all patients - there must also be appropriate and timely interpretation and intervention. To address this problem of consistency and protocol adherence, a decision support system, "Assisted Fluid Management" (AFM), has been developed to help ease some of the work associated with GDFT protocol implementation. The AFM system (released on the European market in March 2017) may help increase GDFT protocol adherence while leaving direction and guidance in the hands of the care providers. This artificial intelligence-based system can suggest administration of fluid boluses, analyse the hemodynamic effects of the bolus, and continually re-assess the patient for further fluid requirements. This system was recently implemented in a before-and-after study in a Belgian academic hospital, where the authors reported that the implementation of this AFM software system allowed a better adherence to the GDFT algorithm. However, as this was a pilot study with a small number of patients, the study was not powered to demonstrate a beneficial effect on the incidence of postoperative complications. More recently, a group from the Cleveland Clinic demonstrated that using AFM system resulted in more boluses being effective when compared to the administration of boluses without AFM support. There are no randomized controlled studies to date comparing this AFM system to standard of care on patient outcome. We therefore aim to conduct a multicenter stepped-wedge, cluster-randomized trial involving patients undergoing high risk abdominal surgery to compare a GDFT strategy guided by the AFM system with usual care. A stepped wedge, cluster-randomized trial approach was chosen in which clusters will be randomized to commence the intervention at different times following an initial control period in which outcomes will be measured for usual care. So, each center (cluster) began in the control phase and transitioned to the intervention phase at a randomly assigned time (wedge). The order in which each center will move from control to intervention phase will be randomly allocated by a computer algorithm performed by the study statistician. We selected cluster randomization rather than randomization of individual patients because the control group could be very different among centers (from GDFT strategy using a flow monitoring to GDFT with a written protocol to no clear strategy (use of an arterial line only without any advanced monitoring). Interestingly, this approach also decreases the Hawthorne effect which has been shown to decrease the incidence rate of the primary outcome in recent randomized trials because clinicians know that their patients are included in a research protocol.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date December 30, 2026
Est. primary completion date May 2, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Any adult patient (aged 18 years or older) admitted to the operating room for an elective high-risk abdominal surgery (both open and laparoscopically assisted). - Patients must fulfill at least one of the following high-risk criteria: - American Society of Anesthesiologists physical status > 2 - classification exercise tolerance < 4 metabolic equivalents as defined by the guidelines of the American College of Cardiology/ American Heart Association - renal impairment (serum creatinine =1.3mg/dL or >115 mmol/l or estimated glomerular filtration rate < 90 mL/min/1.73 m2 within the last 6 months) or renal replacement therapy - coronary artery disease (any stage) - chronic heart failure (New York Heart Association Functional Classifcation = II) - valvular heart disease (moderate or severe); - history of stroke - peripheral arterial occlusive disease (any stage) - chronic obstructive pulmonary disease (any stage) or pulmonary fibrosis (any stage) - diabetes mellitus requiring oral hypoglycemic agent or insulin; immunodeficiency due to a disease (e.g., HIV, leukemia, multiple myeloma, solid organ cancer) or therapy (e.g., immunosuppressants, chemotherapy, radiation, steroids) - liver cirrhosis (any Child-Pugh class) -- body mass index =30 kg/m2 - current smoking or 15 pack-year history of smoking - All participants must receive clear study information and give signed informed consent Exclusion Criteria: - Patients with preoperative cardiac arrhythmias (atrial fibrillation) as the monitoring devices are not accurate under cardiac arrhythmias. - No affiliation with the French health care system - Patients participating in another randomized controlled trial with the same clinical endpoint, or interventions possibly compromising the primary outcome. - Pregnant patients - Patient on AME (state medical aid) (unless exemption from affiliation) - Patients guardianship/legal protection/curatorship

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Routine care
Fluid administration will be given per routine care MAP between 65 - 70 mmHg
Device:
AFM
AFM will recommand fluid bolus administration and MAP will be maintained between 65 and 70 mmHg

Locations

Country Name City State
Belgium UZ Brussels Brussel
Canada CHUM Montreal Montréal Montreal
France CHU Clermont-Ferrand Clermont-Ferrand
France Chu Dijon Dijon
France ALEXANDRE JOOSTEN, MD PhD Le Kremlin-Bicêtre
France BICETRE Le Kremlin-Bicêtre Paris
France Centre chirurgical Marie Lannelongue Le Plessis-Robinson Haut De Seine
France Chu Lille Lille
France Centre hospitalier universitaire de NANCY Nancy
France BEAUJON Paris
France HEGP Paris
France Insititut Mutualiste Montsouris Paris
France La Pitie Salpetriere Paris
France Chu Toulouse Toulouse
Germany University Medical Center Hamburg-Eppendorf Hamburg
United States University of California IRVINE Irvine California
United States University of California Los Angeles (UCLA) Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  France,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Composite endpoint ("any event versus none") of major postoperative complications within 30 days after surgery It includes : acute myocardial injury, including myocardial infarction, acute kidney injury, severe infectious complications (including deep surgical site infection, pneumonia, sepsis, peritonitis), anastomotic leakage, pulmonary embolism or venous thrombosis, pulmonary edema, acute respiratory distress syndrome, de novo arrhythmia, stroke, reoperation for any cause, non-fatal cardiac arrest, and mortality within 30 days after surgery Postoperative day 30
Secondary Incidence of each of the individual components of the composite primary outcome within 30 days after surgery Postoperative day 30
Secondary Incidence of the composite primary outcome within 7 days after surgery Postoperative day 7
Secondary Incidence of a composite of postoperative infection rate within 30-day of surgery. This is defined as one or more of the following infections: surgical site infection, organ space surgical-site infection, urinary tract infection, laboratory-confirmed blood stream infection or infection, source uncertain (this is defined as an infection which could be more than one of the above but it is unclear which) Postoperative day 30
Secondary Clavien-dindo classification score Postoperative day 30
Secondary Comprehensive complication index (CCI) Postoperative day 30
Secondary Length of stay in the hospital Postoperative day 30
Secondary Incidence of unplanned hospital re-admission within 30 days after surgery Postoperative day 30
Secondary Mortality rate at 90 days after surgery. Postoperative day 90
See also
  Status Clinical Trial Phase
Completed NCT05268419 - Efficacy and Safety of Ethanol Inhalation on COVID-19 Treatment (a Clinical Trial Study) Phase 3
Completed NCT03251573 - The Cohort Study of Cognitive Impairment in Chinese Hemodialysis Patients
Completed NCT04238806 - Desflurane,Brain Natriuretic Peptide and Cardiac Surgery N/A
Enrolling by invitation NCT05161104 - A Multicenter Cross-sectional Study of Cardiac Ultrasound Phenotypes in Patients With Sepsis
Recruiting NCT03893136 - The Registry Study of Takayasu Arteritis in East China
Recruiting NCT03305276 - Observatory on Impact of Life Styles on Health Outcomes N/A
Recruiting NCT04963530 - Enamel Wear Evaluation in Patients With Different Ceramic Restorations N/A
Withdrawn NCT03022877 - Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions N/A
Completed NCT02041403 - RENAL RESISTIVE INDEX POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY? N/A
Withdrawn NCT01356446 - Checklist Application and Mortality N/A
Withdrawn NCT01343069 - Safety Improvement and Checklist Application N/A
Not yet recruiting NCT04918953 - Factors Influencing the Prognosis of Olfactory Dysfunction After Upper Sensation Phase 2
Completed NCT03765372 - Evaluation of BIomarkers for POstoperative Complications in Non-cardiac Surgery Patients
Completed NCT05133960 - The Turkish Version of the Activity Diversity Questionnaire
Completed NCT03247049 - Prognosis in Intracerebral Hemorrhage. The ICHCat Score in Primary Care. N/A
Recruiting NCT03143595 - Clinical Outcomes in Elderly Patients With Preoperative Cognitive Dysfunction N/A
Not yet recruiting NCT06087939 - Outcome and Predictors of Mortality of Patients on Prolonged Mechanical Ventilation
Recruiting NCT01755819 - Outcome and Tunnel Widening After ACL Reconstruction: Comparison of Aperture and Cortical Fixation N/A
Recruiting NCT04979741 - Recovery After Intensive Care Study
Completed NCT04746326 - Treatment in Right Colon Diverticulitis Patients N/A